moxifloxacin has been researched along with Cardiovascular Diseases in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hardin, JW; Hyche, S; Magagnoli, J; Sutton, SS | 1 |
| Li, W; Wang, J | 1 |
| Chan, KA; Chang, CH; Chou, HW; Lai, CL; Lai, MS; Wang, JL | 1 |
| Iannini, PB | 1 |
1 review(s) available for moxifloxacin and Cardiovascular Diseases
| Article | Year |
|---|---|
The safety profile of moxifloxacin and other fluoroquinolones in special patient populations.
Topics: Aged; Anti-Bacterial Agents; Aza Compounds; Bacterial Infections; Cardiovascular Diseases; Fluoroquinolones; Glucose; Homeostasis; Humans; Kidney Diseases; Liver Diseases; Metabolic Diseases; Moxifloxacin; Population Groups; Quinolines; Risk Factors | 2007 |
3 other study(ies) available for moxifloxacin and Cardiovascular Diseases
| Article | Year |
|---|---|
Appraisal of the cardiovascular risks of azithromycin: an observational analysis.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Azithromycin; Cardiovascular Diseases; Clarithromycin; Female; Humans; Levofloxacin; Male; Middle Aged; Moxifloxacin; Retrospective Studies; Risk Factors; Young Adult | 2017 |
Test hysteresis in pharmacokinetic/pharmacodynamic relationship with mixed-effect models: an instrumental model approach.
Topics: Cardiovascular Diseases; Dose-Response Relationship, Drug; Fluoroquinolones; Humans; Models, Biological; Moxifloxacin | 2014 |
Risks of cardiac arrhythmia and mortality among patients using new-generation macrolides, fluoroquinolones, and β-lactam/β-lactamase inhibitors: a Taiwanese nationwide study.
Topics: Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Arrhythmias, Cardiac; Azithromycin; beta-Lactamase Inhibitors; Cardiovascular Diseases; Ciprofloxacin; Clarithromycin; Comorbidity; Female; Fluoroquinolones; Humans; Levofloxacin; Logistic Models; Male; Moxifloxacin; Risk; Taiwan | 2015 |